跳至主要内容
临床试验/CTRI/2020/12/029950
CTRI/2020/12/029950尚未招募2 期

Sublingual Buprenorphine versus Oral immediate-release Morphine for Controlling Breakthrough pain in Cancer Patients referred to Specialist Palliative Care Services- A phase II Randomized Controlled Study

A0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
A

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Age >18 years.
  • 2.Cancer patients referred to or following up specialist palliative care services in the clinic or on home care.
  • 3.History of breakthrough pain (as assessed by Davies Algorithm) and not taking rescue doses.
  • 4.Patient receiving oral morphine for treatment of background pain.
  • 5.Current prescribed oral morphine dose 60mg - 180mg/day for background pain but not taking rescue doses for BTcP.
  • 6.Patient at the time of screening visit experience his/her current BTcP episodes to be severe enough that he/she will require additional analgesia.
  • 7.Willing to take part in the study
  • 8.Patients residing in Mumbai for a period of 2 weeks after recruitment into study/baseline assessment.

排除标准

  • 1.Patients on opioid detoxification programme or Opioid Substitution Therapy
  • 2.Patients on combination opioid therapy
  • 3.Contra-indications to buprenorphine ie. hypersensitivity to Buprenorphine

研究者

发起方
A

相似试验

Sublingual Buprenorphine versus Oral Morphine for... | 临床试验